1 / 38

Regulation: when less is more

Regulation: when less is more. Counterfactual. WHO – 1 billion deaths. One billion. I smoked for 45 years and tried every NRT product available, none of them worked. I continued to smoke even though my health was getting worse, resulting in COPD and using oxygen daily.

iokina
Download Presentation

Regulation: when less is more

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Regulation: when less is more Counterfactual www.clivebates.com @clive_bates

  2. WHO – 1 billion deaths

  3. One billion

  4. I smoked for 45 years and tried every NRT product available, none of them worked. I continued to smoke even though my health was getting worse, resulting in COPD and using oxygen daily. September 2011 I discovered e-cigarettes and they worked. It was like someone handed me a miracle. In less than a week I stopped using regular cigarettes. I haven’t had a tobacco cigarette since. Unsolicited comment left on www.clivebates.com

  5. From WHO Tobacco Atlas 2006 edition

  6. The Endgame? Smokers: WHO Tobacco Atlas 2006. Population: UN

  7. The Endgame? Smokers: WHO Tobacco Atlas 2006. Population: UN

  8. The endgame? Scenario – 15% global prevalence by 2050

  9. The endgame? Scenario – 15% global prevalence by 2050

  10. If all goes well HARM

  11. The endgame – a nicotine product contest?

  12. How far could low-risk nicotine products go?

  13. How far could low-risk nicotine products go?

  14. The endgame: analyst view Consumption of e-cigs may overtake traditional cigarettes in the next decade … and they’ll only evolve and improve as time goes forward. Bonnie Herzog, Wells Fargo Securities, 2013

  15. The endgame: analyst view Consumption of e-cigs may overtake traditional cigarettes in the next decade … and they’ll only evolve and improve as time goes forward. Bonnie Herzog, Wells Fargo Securities, 2013

  16. 50:50 by 2030

  17. Who is this? Mitch Zeller (now) Director of the Center for Tobacco Products FDA

  18. Harm reduction equation Harm reduction = Reduced risk x Number who switch Product toxicity & other risks Product attractiveness Consumer preference

  19. Harm reduction equation Harm reduction = Reduced risk x Number who switch Product toxicity & other risks Product attractiveness Consumer preference

  20. Harm reduction categories – risk estimates

  21. Focus on the right relative risk More regulation Lower risk “unregulated” e-cig regulated e-cig 0 10 100 100 0 cigarette e-cigarettes

  22. Harm reduction equation Harm reduction = Reduced risk x Number who switch Product toxicity & other risks Product attractiveness Consumer preference

  23. Analysts We remain very bullish on the vast potential of e-cigs given the rapid pace of innovation. [We believe] that the benefits of e-cigs are becoming increasingly apparent to consumers, helping to drive trial and repeat purchases aided by stepped-up advertising and a lot of internet “buzz” Wells Fargo

  24. Regulation comes at a price

  25. Harm reduction equation Harm reduction = Reduced risk x Number who switch Trade offs Conclusion 1. The perfectly risk free product that no-one wants scores badly in the harm reduction equation Conclusion 2. A diverse range of products with substantially reduced risk lets each smoker decide which product is best

  26. Triple negative Tough on harm reduction

  27. Specialised medicines language Consistent drug dosing Quality Treats or prevents disease Adverse drug reactions Efficacy Safety

  28. Getting tough on harm reduction? Like tobacco Adults Pharmacies / as tobacco Fear of ‘renormalisation’ Like medicines Warns of danger Counter-productive Control processes (eg. GMP) Safest possible Regulator decides Encourages switching Proportionate standards Consumer decides Harm reducing Like consumer products General sales Makes little real difference Fiscal incentive to switch Safe enough Normalise harm reduction Safety Quality Efficacy Labelling Marketing Bans on use Retail Age restrictions Taxation

  29. What do analysts think…? We believe many current suppliers would struggle to meet medical standards, and for the UK they may have to by 2016. Big players with deeper pockets would survive and prices could rise – a hugely preferable outcome for Tobacco. BNP Paribas Tougher regulation, as well as providing a relative advantage to their e-cigarette divisions, would result in higher prices for e-cigarettes – which could also benefit tobacco companies by limiting their attraction for smokers and slowing the decline in tobacco sales. Fitch

  30. What do analysts think…? We believe many current suppliers would struggle to meet medical standards, and for the UK they may have to by 2016. Big players with deeper pockets would survive and prices could rise – a hugely preferable outcome for Tobacco. BNP Paribas Tougher regulation, as well as providing a relative advantage to their e-cigarette divisions, would result in higher prices for e-cigarettes – which could also benefit tobacco companies by limiting their attraction for smokers and slowing the decline in tobacco sales. Fitch

  31. European Parliament – amendment 170 • Requires medicines regulation if claim made • Requires Article 17 notification regime otherwise • Emphasises general safety requirement • Applies Article 16 – cross border distance sales • Applies advertising directive 2003/33/EC and audiovisual services 2010/13/EU • Information leaflet • Warning “this product is intended for use by existing smokers. It contains nicotine which is a highly addictive substance” • Warning size - 30% or 40% (Council =30%) and specification from Article 10 • 30mg/ml threshold – “are not placed on the market” (?medicine) • Age restriction (no less than 18) • Restriction on additives – application of Article 6.4 (vitamins etc) • No tobacco branding • Allows flavourings • Requires sales allowed ‘outside pharmacies’ • Review

  32. Purpose built regulation for e-cigs / NCPs • Accountabilities – responsible person • Disclosure and notification regime • Labeling and consumer information • Safety assessment and product file • Contaminants / purity • Prohibited ingredients • Specific standards for vapingdevices CEN/ISO • Updating: review & technical committee • Marketing (like alcohol?) – mostly member state • Retail sales age restriction – member states • … public vaping?

  33. Harm reduction equation with population effects Harm reduction = Reduced risk x Number who switch - Extra smokers + Extra quitters Gateway exits Complete cessation Extra quitting Normalising non-smoking Gateway to smoking Dual use Reduced quitting Normalising smoking

  34. Conclusion • Be positive about the (vast) potential • Put the (minor) risks in perspective • Regulate as though the 1 billion matter most

  35. Thank you… Counterfactual www.clivebates.com @clive_bates

More Related